Abstract
Objective: To investigate the clinical efficacy of the MyoSure hysteroscopic tissue removal system in the treatment of benign intrauterine lesions. Methods: Retrospective analysis was performed on the clinical data of 740 patients treated with the MyoSure hysteroscopic tissue removal system for benign intrauterine lesions from September 2014 to December 2018, including 131 cases of submucosal myomas, 85 cases of endometrial polyps and 524 cases of RPOC. The clinical efficacy of MyoSure surgery was analyzed according to patients’ intraoperative conditions (intraoperative blood loss, operative time, lesion complete resection rate, and intraoperative complications) and postoperative symptom relief rate. Results: All 740 patients successfully completed the operation. The intraoperative blood loss was 17.09±14.87ml, 11.78±10.89ml and 29.50±13.74ml for submucosal myomas, endometrial polyps and RPOC, respectively, and the operative time was 42.37±19.33min, 20.96±8.99min and 30.47±14.04min, respectively. The complete resection rates (CRRs) of type 0, type Ⅰ and type Ⅱ lesions and mixed type fibroids were 100.0% (45/45), 96.00% (48/50), 85.67% (13/15) and 75.00% (9/12), respectively. For endometrial polyps and RPOC, the CRRs were 100% (85/85) and 98.28% (515/524), respectively. No intraoperative complications, such as uterine perforation, were reported with the exception of one patient with RPOC who exhibited TURP syndrome during the operation. The postoperative satisfaction rates for submucosal myomas, endometrial polyps and RPOC were 94.66% (124/131), 100.0% (85/85) and 98.85% (518/524), respectively. The conception rate was 47.91% (172/359), and the live birth rate was 59.30% (102/172). Conclusions: The MyoSure hysteroscopic tissue removal system is a safe and effective new treatment for benign intrauterine lesions for women of childbearing age.
Massive hemorrhage after resection of uterine endocervical polyp and endometrial polyps with hysteroscopic tissue removal system
